Implantable materials may be used as spacers for separating tissues to reduce a dose of radioactivity received by one of the tissues. Applications include introducing a hydrogel spacer to a position between a first tissue location and a second tissue location to increase a distance between the first tissue location and the second tissue location, Further, there may be a step of administering a dose of radioactivity to at least the first tissue location or the second tissue location and/or a step of visualizing margins of the hydrogel spacer. A hydrogel spacer may comprise a polysaccharide and a radioopaque agent and may be used for fiducial marking.

The present disclosure relates to methods for radiolabelling PSMA binding ligands with a radioactive isotope, preferably .sup.68Ga, .sup.67Ga or .sup.64Cu, and their kits.

The present invention related to a combination of radium-224 (.sup.224Ra) and/or progeny of .sup.224Ra, and a DNA repair inhibitor for use in the treatment of cancer. The DNA repair inhibitor can for example be a poly (ADP-ribose) polymerase inhibitor (PARPi), a MGMT inhibitor, a DNA-dependent protein kinase inhibitor (DNA-PK inhibitor), an ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor, an ataxia telangiectasia mutated (ATM) kinase inhibitor, a Wee1 kinase inhibitor, or a checkpoint kinase 1 and 2 (CHK 1/2) inhibitor. The radium-224 (.sup.224Ra) and/or progeny of .sup.224Ra can be comprised in nano- and/or micro sized particles.

An implantable device comprising a nanochanneled membrane is described. The device uses nanofluidics to control the delivery of diagnostic and/or therapeutic agents intratumorally. The devices can be used for chemotherapy, radiosensitization, immunomodulation, and imaging contrast.

A method for producing .sup.225Ac solution includes steps (I) to (III): a step (I) of passing a solution containing .sup.226Ra and .sup.225Ac through a solid-phase extraction agent (a) that contains a compound represented by formula (A) so as to cause the solid-phase extraction agent (a) to retain .sup.225Ac; a step (II) of passing a liquid containing an eluate, which is obtained by eluting the retained .sup.225Ac from the solid-phase extraction agent (a), through a solid-phase extraction agent (b) that contains a compound represented by formula (B) so as to cause the solid-phase extraction agent (b) to retain .sup.225Ac; and a step (III) of eluting the retained .sup.225Ac from the solid-phase extraction agent (b) to obtain an .sup.225Ac solution.

##STR00001##

##STR00002##

The invention provides a system for the in vivo treatment of diseased tissue, the system comprising a first longitudinally extending surface and a second longitudinally extending surface coaxial to the first longitudinally extending surface to form a medicament carrying vehicle, wherein the vehicle defines a tunnel adapted to allow physiological fluid to pass through the vehicle. Also provided is method for treating, in vivo, diseased tissue, the method comprising inserting a housing into a tumor excision site and removably sliding a medicament vehicle within the vehicle so as to be encapsulated by the housing.

A radiopeptide is provided which comprises (a) a radionuclide, wherein the radionuclide is terbium-161, (b) a chelator coordinating terbium-161, and (c) a peptide or peptide analogue, which is a somatostatin receptor (SSTR) antagonist. The radiopeptide is suitable for use in the treatment of tumor diseases.

Provided herein are radiopharmaceutical compositions and uses thereof. The radiopharmaceutical compositions can comprise one or more stabilizing agents, an aqueous vehicle, and a conjugate that comprises a targeting ligand and a radionuclide bound to a metal chelator. The targeting ligand can be a small molecule compound or a peptide such as a monocyclic peptide. The targeting ligand can be configured to bind with a tumor target. The stabilizing agent can comprise a radiolysis stabilizer, a free metal chelator, and/or a pH stabilizer. Further provided herein are methods of preparing the radiopharmaceutical compositions and methods of treating cancer by administering the described radiopharmaceutical compositions.

A nuclear medicine infusion system (10) may be used to generate and infuse radioactive liquid into a patient undergoing a diagnostic imaging procedure. In some examples, the infusion system includes a frame (30) that carries a radioisotope generator (52) that generates radioactive eluate via elution. The frame may also carry a beta detector (58) and a gamma detector (60). The beta detector can be positioned to measure beta emissions emitted from the radioactive eluate supplied by the generator. The gamma detector can be positioned to measure gamma emissions emitted from a portion of the radioactive eluate to evaluate a safety of the radioactive eluate delivered by the infusion system.

Polarized nuclear imaging and spectroscopy systems and methods are disclosed. In some embodiments, nuclei of a radioactive substance are polarized such that the spins of the nuclei are oriented in a specific direction, to generate a polarized radioactive tracer with anisotropic gamma ray emission. The radioactive substance is selected such that the degree of anisotropy is enhanced. A tracer is introduced into a living subject for delivery to a target area of interest in the subject. The tracer is delivered such that nuclear spin relaxation of the tracer is inhibited during transport of the tracer to the target area of interest. Gamma rays from the gamma ray emission are detected, and based on the detected gamma rays and properties associated with the anisotropic gamma ray emission, imaging data and/or spectroscopic data are obtained that are associated with the tracer in the subject. In some embodiments, a radioactive substance is delivered to a target area of interest in the subject and the nuclei of the radioactive substance are polarized following delivery of the radioactive substance to the target area of interest, such that the spins of the nuclei are oriented in a specific direction, to generate a polarized radioactive tracer with anisotropic gamma ray emission. Gamma rays are detected from the gamma ray emission, and based on the detected gamma rays and properties associated with the anisotropic gamma ray emission, imaging data and/or spectroscopic data are obtained that are associated with the tracer in the subject.